Navigating Late Line R/R Multiple Myeloma: Treatment Landscape, Patient Care, and Quality of Life - Episode 4

Current Treatment Landscape for Late-Line RRMM

March 24, 2025
Saad Usmani, MD

,
Amrita Krishnan, MD

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.

Video content above is prompted by the following:

  • What is the current treatment landscape for patients who have late-line RRMM?